GBA Presents: RADIO SAVANT-!

TrailerParkTed · Dec 30, 2022

Van, ATNF is holding out well. Any thoughts? The next Pali?

TrailerParkTed · Dec 30, 2022

stonedinvestor said:
I go to Dr soon. Leave you with this--

So ARDX-- It got a rare reversal by the FDA... they will now be able to submit...

This has set off a lot of debate.. Most analysts are hype on thei dea now....

Show Full Stories Send Info

Citi ups Ardelyx target, sees approval odds 'nearly 100%' 16:04
ARDX
Citi analyst Yigal Nochomovitz raised the firm's price target on Ardelyx to $7 from $6 and keeps a Buy rating on the shares after the FDA granted the appeal to the Complete Response Letter for Xphozah. The analyst does not believe the market is "appropriately absorbing the magnitude of this unprecedented regulatory reversal." The hat the Complete Response Letter has been formally overturned and the probability of approval in 2023 is "nearly 100%," Nochomovitz tells investors in a research note. As such, the analyst raised Xphozah's probability of success for Xphozah to 97.5%.

Ardelyx approval for tenapanor 'still far from a slam dunk,' says Wedbush 10:12
ARDX
After Ardelyx disclosed that FDA's Office of New Drugs has issued an Appeal Granted Letter in its formal dispute resolution request after the company previously received a Complete Response Letter for tenapanor in hyperphosphatemia, Wedbush analyst Laura Chico said there are more regulatory hurdles to cross. While this opens a path forward for tenapanor and represents "a much-needed win" for Ardelyx, approval is "still far from a slam dunk," Chico tells investors. She awaits greater clarity on potential labeling and populations before layering in the tenapanor in hyperphosphatemia opportunity to her estimates and maintains a Neutral rating on Ardelyx shares with a $2 price target.

Ardelyx price target raised to $3 from $1.60 at Cantor Fitzgerald 10:03
ARDX
Cantor Fitzgerald analyst Louise Chen raised the firm's price target on Ardelyx to $3 from $1.60 and keeps a Neutral rating on the shares after the FDA granted the appeal to the Complete Response Letter for Xphozah. This is "clearly good news for the company," Chen tells investors in a research note. However, the analyst remains on the sidelines pending greater earnings visibility in 2023 and beyond.

Show Related Items >>

Ardelyx approval odds 'very high' after FDA grants appeal, says Piper 10:00
ARDX
Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Ardelyx with an $8 price target after the FDA granted the appeal to the Complete Response Letter for Xphozah. The appeal grant comes with FDA's direction for the company to work with the Division of Cardiology and Nephrology to develop an appropriate label, which the company believes could be directed at patients whose hyperphosphatemia is insufficiently managed on phosphate binders, Raymond tells investors in a research note. He believes the likelihood of Xphozah getting approved are "very high after today's decision." Raymond continues to like the stock's risk/reward, saying it is "heavily positively skewed at this point." Shares of Ardelyx are down 11% to $2.33 in early trading.

More...

Stoney remember I mentioned ARDX?

vanzandt · Dec 30, 2022

TrailerParkTed said:
Stoney remember I mentioned ARDX?
More...

Look at a 6 month chart of Under Armour.
What do you call that? A cup & handle?
Inverted h&s?

The 50 day just crossed the 100 from belowlast week.
No debt.
And it's cheap enough to become the next meme stock for the WSB's folks.

I like it for 2023 Ted.
I mean it won't set the world on fire, unless of course it does become a meme stock, but it looks pretty safe at this point in the game.

UA---> $8.89

TrailerParkTed · Dec 30, 2022

TrailerParkTed said:
Van, ATNF is holding out well. Any thoughts? The next Pali?
More...

Heading to $4, I bought the FUTU $40puts at $1.8 ave, out $2.40-$2.50.

ATNF breaking $4?

TrailerParkTed · Dec 30, 2022

vanzandt said:
Look at a 6 month chart of Under Armour.
What do you call that? A cup & handle?
Inverted h&s?

The 50 day just crossed the 100 from belowlast week.
No debt.
And it's cheap enough to become the next meme stock for the WSB's folks.

I like it for 2023 Ted.
I mean it won't set the world on fire, unless of course it does become a meme stock, but it looks pretty safe at this point in the game.

UA---> $8.89
More...

I agree, I love UA! I own GPS, ULTA, ANF, DKS, NKE.

TrailerParkTed · Dec 30, 2022

Stoney our VRNA took out its 52 week high! Did you evaluate PDSB? I bought some at $10-$12, holding for $15? What say you?

TrailerParkTed · Dec 30, 2022

Happy New Year Savant and Stoney! Wanted to thank you for all the hard work and great ideas you posted in 2023! Wishing you and your family a great 2023!

vanzandt · Dec 30, 2022

stonedinvestor said:
Under Armour, Inc. (UA)
NYSE - Nasdaq Real Time Price.
6.20-0.02(-0.40%)<------ GO TIME!
As of 10:12AM EDT.
More...

It's not go time until VZ says it's go time.
Consolidation complete, 50 day cross... go time confirmed.
>>>It's go time.

stonedinvestor · Dec 30, 2022

TrailerParkTed said:
Stoney remember I mentioned ARDX?
More...

THAT'S WHY I DID SOME DD ON IT! TED YOU HAVE THE HOT HAND...!

stonedinvestor · Dec 30, 2022

TrailerParkTed said:
Happy New Year Savant and Stoney! Wanted to thank you for all the hard work and great ideas you posted in 2023! Wishing you and your family a great 2023!
More...

THIS IS LIKE THE PENGUINS SIGNING OFF! SOP SAD

WHAT ARE WE GOING TO DO IN THE NEW YEAR?

VAN WILL YOU BE DABBLING THE FRONT BOARD WITH VARIOUS THREADS I CAN TAG ONTO?